1-Year Follow-up of a Phase 3 Study to Compare Efficacy and Safety of a Bevacizumab Biosimilar, CT-P16, and Reference Bevacizumab, Avastin(r), as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
CT-P16;Avastin;Bevacizumab
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: 1-Year Follow-up of a Phase 3 Study to Compare Efficacy and Safety of a Bevacizumab Biosimilar, CT-P16, and Reference Bevacizumab, Avastin(r), as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer ### Output: CT-P16;Avastin;Bevacizumab